MSI-H Clinical Trials

26 recruitingLast updated: June 18, 2026

There are 26 actively recruiting msi-h clinical trials across 15 countries. Studies span Phase 2, Phase 1, Phase 3, Early Phase 1, Not Applicable. Top locations include Guangzhou, Guangdong, China, Houston, Texas, United States, Toronto, Ontario, Canada. Updated daily from ClinicalTrials.gov.


MSI-H Trials at a Glance

26 actively recruiting trials for msi-h are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Guangzhou, Houston, and Toronto. Lead sponsors running msi-h studies include Sun Yat-sen University, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), and Akeso.

Browse msi-h trials by phase

Treatments under study

About MSI-H Clinical Trials

Looking for clinical trials for MSI-H? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MSI-H trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MSI-H clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled16 locationsNCT07403721
Recruiting
Phase 1Phase 2

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University28 enrolled1 locationNCT05426005
Recruiting
Phase 2

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Gastric CancerColon CancerMSI-H+1 more
Peking University34 enrolled1 locationNCT06580574
Recruiting
Early Phase 1

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Massachusetts General Hospital15 enrolled1 locationNCT07128355
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Advanced Solid Tumors CancerMSI-H Cancer
Nimbus Wadjet, Inc.134 enrolled22 locationsNCT06898450
Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Non-small Cell Lung CancerMelanoma (Skin Cancer)Invasive Mammary Carcinoma+5 more
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting
Phase 2

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 3

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

MSI-H/dMMR Colorectal CancerResectable Colon Cancer
Akeso386 enrolled1 locationNCT07412613
Recruiting
Phase 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Gastric CancerMetastatic CancerAdvanced Cancer+1 more
Centre Leon Berard132 enrolled6 locationsNCT06346197
Recruiting
Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Colorectal, CancerGastric CancerEndometrial Cancer+4 more
MOMA Therapeutics132 enrolled14 locationsNCT06974110
Recruiting
Phase 2

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Esophageal CancerCervical CancerHepatocellular Carcinoma+9 more
Diwakar Davar880 enrolled1 locationNCT07223424
Recruiting
Phase 1Phase 2

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Colorectal, CancerHepatocellular CarcinomaMelanoma+15 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting
Phase 1Phase 2

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting

Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer

Colo-rectal Cancer (dMMR/MSI-H CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled1 locationNCT07352280
Recruiting
Early Phase 1

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Endometrial CancerNon-small Cell Lung CancerTNBC - Triple-Negative Breast Cancer+6 more
Radiopharm Theranostics, Ltd30 enrolled5 locationsNCT06305962
Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Liver CancerColorectal, CancerEndometrial Cancer+12 more
Elephas2,000 enrolled8 locationsNCT07327489
Recruiting
Phase 2

Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

Colorectal, CancerNeoadjuvant TherapyMismatch Repair-deficient (dMMR)+1 more
Sun Yat-sen University270 enrolled1 locationNCT03926338
Recruiting
Phase 2

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust50 enrolled9 locationsNCT06250036
Recruiting
Phase 1Phase 2

A Beta-only IL-2 ImmunoTherapY Study

Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 1

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Liver CancerEsophageal CancerGastric Cancer+9 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)18 enrolled1 locationNCT07001592